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Mono- and biphasic kinetic effects of bile salts on the pancreatic IB phospholipase A2 (PLA2) catalyzed interfacial hydrolysis are
characterized. This novel phenomenon is modeled as allosteric action of bile salts with PLA2 at the interface. The results and controls also show
that these kinetic effects are not due to surface dilution or solubilization or disruption of the bilayer interface where in the mixed-micelles substrate
replenishment becomes the rate-limiting step. The PLA2-catalyzed rate of hydrolysis of zwitterionic dimyristoylphosphatidylcholine (DMPC)
vesicles depends on the concentration and structure of the bile salt. The sigmoidal rate increase with cholate saturates at 0.06 mole fraction and
changes little at the higher mole fractions. Also, with the rate-lowering bile salts (B), such as taurochenodeoxycholate (TCDOC), the initial
sigmoidal rate increase at lower mole fraction is followed by nearly complete reversal to the rate at the pre-activation level at higher mole
fractions. The rate-lowering effect of TCDOC is not observed with the (62–66)-loop deleted ΔPLA2, or with the Naja venom PLA2 that is
evolutionarily devoid of the loop. The rate increase is modeled with the assumption that the binding of PLA2 to DMPC interface is cooperatively
promoted by bile salt followed by allosteric kcat⁎-activation of the bound enzyme by the anionic interface. The rate-lowering effect of bile salts is
attributed to the formation of a specific catalytically inert E⁎B complex in the interface, which is noticeably different than the 1:1 EB complex in
the aqueous phase. The cholate-activated rate of hydrolysis is lowered by hypolidemic ezetimibe and guggul extract which are not interfacial
competitive inhibitors of PLA2. We propose that the biphasic modulation of the pancreatic PLA2 activity by bile salts regulates gastrointestinal fat
metabolism and cholesterol homeostasis.
© 2007 Elsevier B.V. All rights reserved.Abbreviations: Analytical parameters are defined in Scheme A1 in
Appendix A. Structures of the bile salts and conjugates are given in Figure 1.
DMPC, 1,2-dimyristoyl-sn-3-glycerophospho-choline; DMPM, 1,2-dimyris-
toyl-sn-3-glycerophospho-methanol; DOC, deoxycholate; DTPC, 1,2-ditetrade-
cyl-rac-3-glycerophosphocholine; i-face, the interface binding surface of PLA2;
LPC, 1-myristoyl-sn-3-glycerophospho-choline; MA, myristic acid; MJ33, 1-
hexadecyl-3-(trifluoroethyl)-rac-glycero-2-phosphomethanol; PGU, 2-dodeca-
nylamino-hexanol-2-phosphoglycol; PLA2, group IB phospholipase A2 from
pig pancreas; POPC, 1-palmitoyl-2-oleoyl-sn-3-glycerophospho-choline; pro-
ducts, LPC+MA (1:1); TCDOC, taurochenodeoxycholate; TDOC, taurodeox-
ycholate; TMA-DPH, trimethylammonium-diphenylhexatriene; WT, wild type
PLA2
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Gastrointestinal uptake of dietary fat and its metabolic
consequences is a major human health concern [1–3]. Fat
emulsion in the digestive tract encounters in stages bile salts
secreted with the gastric, pancreatic and intestinal enzymes
including pancreatic IB phospholipase A2 (PLA2)
1 and lipases.
The resulting changes in emulsion properties are likely to
influence the interfacial kinetics of action of gastrointestinal
enzymes [4–9], and therefore play a role in the processing and
uptake of the emulsion components [1,3,10–13]. Triglycerides
provide most of the fat-derived calories and phospholipids
account for b5%. On the other hand, fat uptake is modified
under conditions where bile salt and PLA2 secretion is affected,
such as in pancreatitis, cholestasis, formation of gallstone, and
gall bladder surgery. A role for the processing of dietary
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suggested in the PLA2 deficient mice or the effect of inhibitors
of PLA2 [1,3,14,15]. These observations suggest a role of bile
salts and pancreatic PLA2 in the regulation of digestion, uptake
and excretion of dietary fat.
Our hypothesis is that the gastrointestinal substrate for the
pancreatic PLA2 is the phospholipid monolayer surrounding the
dietary fat emulsion with a core of nonpolar triglycerides and
cholesterol esters. Action of PLA2 on the monolayer would
change the surface area and charge. The decrease in the surface
area would increase the particle size so as to retain the total
volume of the nonpolar components in the hydrophobic core of a
reduced number of larger particles. Changes in the surface
composition, as well as the area, volume and dispersity of
emulsion, initiated by PLA2 and bile salt would therefore re-
gulate the emulsion behavior at appropriate stages in the
gastrointestinal tract. Constraints on interfacial kinetic behavior
of the lipolytic enzymes [6,16,17] are such that the processing of
emulsion surface would alter susceptibility and accessibility of
the emulsion components. In turn regulation of the accessibility,
metabolism, and absorption of the emulsion components is
likely to influence the ultimate balance of the uptake versus
excretion of emulsion with far reaching health consequences.
The species-specific composition and concentration of
gastrointestinal bile salts and conjugates (Fig. 1) appears to
depend on the dietary and disease states. Little attention has
been paid to the structure-specific kinetic effects of bile salts.
Anionic amphiphiles, including bile salts, change the rate of
hydrolysis of phosphatidylcholine vesicles by pancreatic PLA2
[18–22] by promoting the binding of PLA2 and its allosteric
activation [16,17,23]. In this paper we report a novel kinetic
effect of certain bile salts. Depending on their structure, bile
salts show a mono- or biphasic concentration-dependent effect
on the PLA2 catalyzed rate of hydrolysis of phosphatidylcho-
line zwitterionic interface. Results are interpreted in terms of the
model in Appendix adopted from the interfacial kinetic
paradigm [16,17]. The rate-lowering bile salts (B) apparently
form catalytically inert E⁎B complex in the interface. Properties
of the corresponding EB complex in the aqueous phase, as wellFig. 1. Structures of (from left) masticadienolic acid, ezetimibe, and bile salts wher
ursodeoxycholate. Tauro-bile acids conjugated with taurine (as shown) and glyco-bias the premicellar complexes with other amphiphiles, provide
insights into the behavior of E⁎B, as well as the relationship of
the bile-salt binding to the events of the active site, i-face and
the allosteric site. Results in this paper also show that several
other compounds specifically lower the cholate activated PLA2-
catalyzed rate. The effect of ezetimibe (Fig. 1) is of interest
because it is prescribed to lower intestinal cholesterol absorp-
tion in humans [24–29]. Together we propose that the kinetic
effects of bile salts and other compounds on the PLA2-catalyzed
hydrolysis of dietary phospholipid regulate the gastrointestinal
uptake of dietary fat and cholesterol.2. Materials and methods
Bile salts (Sigma) were crystallized in ethanol to N98% purity. Preparation
and characterization of pig pancreatic IB ΔPLA2 [30], and Trp-substitution
mutants of W3F PLA2 [31] have been described. Human pancreatic IB PLA2
was from Suren Tatulian (Orlando, FL). The 62–66 loop deleted ΔPLA2 and
Naja venom PLA2 DEIII were from Bert Verheij (Utrecht, The Netherlands).
Ezetimibe, the active component of the Zetia pills (Schering-Plough) was
extracted and purified. Its solubility limit of b20 μM in pH 8 buffer precluded
detailed studies. The components of guggul resin were fractionated by taking
advantage of solubility, crystallization, and chromatography on silica gel and
reverse phase column. Guggulosterones, cembrenes and other known [32] as
well as unknown compounds were structurally characterized by spectroscopic
methods. Sources of lipids and reagents as well as rationale for the choice of the
experimental conditions and protocols are established [19,20,33]. Specific
conditions and key protocols relevant to this study are outlined with suitable
references.
2.1. Kinetic measurements
Aqueous dispersion of phospholipid was sonicated in a bath type sonicator,
and virtually transparent vesicle suspension was annealed at room temperature
[18,19]. Reaction progress for the PLA2-catalyzed hydrolysis of the sonicated
DMPC (1 mM) vesicles was measured by pH-stat titration (Radiometer) with
1 mM 2-aminopropanediol base. The reaction mixture (4 ml) in the nitrogen-
purged closed atmosphere in a thermostated glass reaction vessel contained
5 mM CaCl2 for DMPC (or 0.5 mM CaCl2 for DMPM), 1 mM NaCl, and
0.1 mM EDTA at pH 8.0 and 24±0.1 °C [23,34–36]. Anomalous reaction
progress observed in plastic vessel is not interpretable [37]. Reaction was
initiated with about 2 pmole PLA2 in 1–5 μl stock solution in 4 M NaCl and
2 mM (diether) dihexyl-phosphatidylcholine to minimize surface absorption. Ine hydroxyl groups at 3, 7 and 12 normally in α orientation except for 7-OH of
le acids are conjugated with glycine (–NH–CH2–COO
−).
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the reaction progress during the delay. Under most conditions this region lies
between the initial pH-jump that subsides within 2 min and the onset of the burst
phase after 10 min. With suitable precautions estimated uncertainty in the
reported rates is 10%. The pH-stat protocol was also used for monitoring the rate
of hydrolysis of DMPM (0.4 mM) vesicles in the presence of polymyxin B
[35,38,39], or of mixed-micelles of 1 mM POPC with bile salts in 1:2 ratio
[20,40], or of dioctanoylphosphatidylcholine micelles under the low salt
conditions [41]. If suitably adopted and controlled, these kinetic assays provide
significant mechanistic insights [16].
2.2. Fluorescence measurements
Fluorescence emission spectrum or time course of the intensity change from
tryptophan or the energy transfer probe TMA-DPH were measured in the ratio
mode on SLM-Aminco AB2 in a 1 cm cuvette containing 1.6 ml stirred buffer
with 1 or 2 μMPLA2 in 10mMTris, 5mMCaCl2 and 20mMNaCl at pH 8.0 and
24 °C. The slit-widths were 4 nm with excitation at 280 nm. The change in the
fluorescence signal is expressed either as F−F0 or δFmax (=F/F0−1). Specific
conditions and rationale are based on the results of earlier studies [42–46].
2.3. Isothermal calorimetric measurements
ITC titration of PLA2 with b1 mM (below the CMC) bile salt titrant was
carried out with Microcal calorimeter (model VP-itc) with cell volume of
1.42 ml stirred at 300 rpm [42,45]. Successive injections were made every
5 min. Standard software was used for the peak integration. The heat change
associated with the dilution of the titrant (bile salt) in the absence of the enzyme
was subtracted from the heat change in the presence of 8.5 μM PLA2. The net
heat change per injection in the presence of PLA2 was integrated to obtain the
bile salt concentration versus the total heat change plot.3. Results
The allosteric mechanism for the mono- and biphasic effect
of bile salt of PLA2 is characterized on the stationary phase
reaction progress during the course of hydrolysis of zwitterionic
DMPC vesicles by pancreatic PLA2. Typical results are shown
in Fig. 2. We have shown that such complex curves [18,19] areFig. 2. The PLA2 (2 pmol) catalyzed hydrolysis of reaction progress curve for
the hydrolysis of 1 mM DMPC vesicles at 24 °C (continuous line) alone, or in
the presence of 0.05 mM (dotted line top) cholate or (dashed line)
tauroursodeoxycholate (TUDOC) in 2 mM CaCl2 at pH 8.0 and 24 °C. The
burst of activity in the top two curves occurs after a delay of 10 and 20 min,
respectively. The pre-burst rates are slopes in the first 5 min or less. A small
background drift is not subtracted from the curves but it is not included in the
reported rates.modified not only by bile salts [20] but also by other wide
ranging perturbations of the interface including the presence of
products, other amphiphiles, annealing history, and size of
vesicles [16,17,20,35,36,47–51]. Therefore it is necessary to
establish certain constraints for the analysis of the stationary
phase reaction progress [16,49] for the ensemble averaging of
the turnover path. Detailed interfacial kinetic analysis also
requires that the microscopic variables be ascertained. The
model in the Appendix for the analysis of the effects of bile
salts on the stationary phase rate from the reaction progress
in Fig. 2 is based on the requirement that enzyme exchange
between vesicles is sufficiently fast so that for each binding
event only a small number of substrates are hydrolyzed. In this
way, most vesicles will be hydrolyzed to the same extent and
each active enzyme will “see” the same environment. This
assumption is supported by the Kd value of about 0.2 mM
under the kinetic conditions for the pre-burst rate, and it is
likely to be lower with added bile salt and with accumulated
products. Additional constraints and controls are summarized
below.
3.1. Stationary-phase reaction progress
Several features of the reaction progress in Fig. 2 are of
interest. The rate in the pre-burst stationary phase is obtained
from the mid-region of the delay phase where about 2% of the
total substrate is hydrolyzed. The burst of activity at the end of
the delay is due to in situ formation of a critical mole fraction of
the products of hydrolysis [16,18,19,21,49,52,53], which is
about 0.08 in DMPC vesicles at 24 °C. In the absence of an
additive, the pre-burst rate is b10 s−1 compared to the burst rate
of 140 s−1 when 6 to 10% of the substrate is already hydrolyzed.
If DMPC substrate is covesiculated with N0.08 mole fraction
products of its hydrolysis, the delay is b1 min. Also the initial
rate with these ternary vesicles is comparable to the burst rate.
During the pre-burst phase of the reaction progress, the rate of
vesicle-to-vesicle exchange of DMPC is negligible on the time
scale of the reaction progress. Vesicle-to-vesicle exchange of
the products formed in situ is possible within the delay period.
However, net transbilayer and vesicle-to-vesicle exchange of
both products formed in situ is considerably slower than that of
the individual products.
Microscopic variables underlying the delay and the burst rate
are not established. In the model the product formed in situ
during the delay has several effects. The pre-burst rate and the
delay time are sensitive indicators of the changes in Kd of PLA2
bound to the interface. For DMPC vesicles Kd is about 3 mM (in
units determined by the concentration of interface expressed as
monomer DMPC concentration). Here the key consideration is
that the pre-burst rate shows a 5th order dependence on the
interfacial anionic charge density, which we attribute to a
dependence of Kd (Appendix). A high Kd value assures rapid
enzyme exchange between vesicles. Therefore with a 1000-fold
excess of vesicles, the pre-burst phase of the reaction is likely to
occur in the microenvironment for each enzyme molecule
where the anionic charge from the product formed in situ is
uniformly distributed.
Fig. 4. Rate of PLA2 (1.5 pmole) catalyzed hydrolysis of DMPC (1 mM)
vesicles with (unfilled squares) cholate or (filled diamonds) TCDOC. Fits for
three models based on Scheme A1 (Appendix) are shown. Some indepen-
dently determined parameters are used in all fits: KM
0 =KM⁎=0.65 mole frac-
tion, kcat
0 =20 s−1, kcat⁎=240 s
−1, Kd
0 =3 mM, KEB=0.005 mM for TCDOC, and
KEBN1 mM for cholate. Parameters estimated from the fit with cholate are n=5,
Ka=0.024 mole fraction, KEB⁎≫1 mole fraction, K′=0.1 mM. (Model A:a)
Continuous line is the fit for TCDOCwith ideal partitioning and Hill number 1.5
for the formation of E⁎B, KEB⁎=0.03 mole fraction, n=5, Ka=0.02 mole
fraction, K′=0.1 mM. (Model A:b) Dotted line is with ideal partitioning and Hill
number 1 for E⁎B, KEB⁎=0.022, n=5, Ka=0.02 mole fraction, K′=0.1 mM.
(Model B) Dashed line is the fit with nonideal partitioning that saturates at
XB⁎=0.037 mole fraction, K′=0.02 mM, KEB⁎≫1, n=5, Ka=0.023.
2481B.-Z. Yu et al. / Biochimica et Biophysica Acta 1768 (2007) 2478–24903.2. Pre-burst rate depends on the concentration and structure
of bile salt
The delay is expected to be shorter and the stationary pre-
burst rate higher as Kd decreases in the presence of anionic bile
salts. As shown in Fig. 2, this is the case for DMPC vesicles in
the presence of 0.05 mM cholate. Surprisingly however, in the
presence of 0.05 mM tauro-ursodeoxycholate (TUDOC), the
delay increases and the pre-burst rate is also noticeably lower.
The concentration dependence of the pre-burst rate on DMPC
vesicles in the presence of eight bile salts are summarized in
Fig. 3. The key result is that the pre-burst stationary phase rate
depends on the concentration as well as on the structure of the
bile salt. Depending on the structure of the bile salt, the rate
increases up to 15 fold between 0.02 and 0.06 mM. Also
depending on the structure of the bile salt, at the higher
concentrations, the pre-burst rate decreases to the level which in
some cases at 0.15 mM is the same as in the absence of bile salt.
For a detailed characterization of the rate increase and rate-
lowering effects of bile salts, our focus is on the effect of cholate
and TCDOC on the pre-burst rate. In the absence of bile salt, the
pre-burst rate is less than 10 s−1. In the presence of 0.05 mM
cholate, the maximum rate is 140 s−1 and changes little at the
higher concentration. The peak rate at 0.04 mM TCDOC is
about 80 s−1 and decreases at the higher concentrations. At
0.2 mM TCDOC the rate is approximately the same as the rate
in its absence.
3.3. Model for mono- and biphasic kinetic effects of bile salts
Reaction progress in Fig. 2 is obtained under conditions
where the vesicle-to-enzyme ratio is about 1000 with vesicle
size of 10,000 in the outer layer. With modest binding of the
enzyme to vesicles, the reaction progress in the stationary phase
occurs via the interfacial reaction path with predictable change
in the turnover processivity in relation to the dissociationFig. 3. Effect of bile salt concentration on the PLA2 catalyzed pre-burst rate of
hydrolysis of DMPC vesicles (under the conditions in Fig. 2) in the presence of
(from top at about 0.07 mM) #1 cholate, #2 deoxycholate, #3 glycocholate, #4
glyco-DOC, #5 urso-DOC, #6 tauro-DOC, #7 taurocheno-DOC, and #8
taurourso-DOC. In some of these cases the pre-burst rate is not adequately
resolved from the burst rate. Estimated noise level and uncertainty in the
measured rates is about 10% and likely to be different in different regions of
these curves.constant, Kd, of the enzyme from the interface. The ensemble
averaging with such assumptions and independently determined
interfacial turnover parameters [16,48,49] reasonably describes
the complex reaction progress.
As shown in Fig. 4, a model developed in Appendix provides
adequate fit for the monophasic effect of cholate concentration
and the biphasic effect of TCDOC concentration on the pre-
burst rate. The difference can be attributed to a change in a
single step of the scheme A1 within which the alternatives for
the falling phase are also considered. The rate increase is
attributed to the enhanced binding of the enzyme to DMPC
interface in the presence of bile salts or the products of
hydrolysis, to the allosteric effect of the interface on the
substrate binding, and to the chemical step of the interfacial
turnover path [19,42,45,53]. The rate is modeled with the
stationary phase assumptions where Kd for the bound enzyme
decreases with the bile salt concentration. During the observed
reaction progress, the variables in the microenvironment of the
bound enzyme are estimated with the assumption that the
enzyme and bile salt exchange as predicted by Kd and the
partition coefficient K', while product inhibition, as well as
equilibration rates of substrate and products, are assumed to be
negligible [16,17,19,53]. Surface dilution is considered on the
basis of bulk concentrations of the amphiphiles present and
formed in the reaction mixture.
The fit for the rising phase in Fig. 4 is attributed to enhanced
binding of the enzyme with a fifth order dependence on the bile
salt mole fraction in the interface and to the kcat⁎-activation of
the bound enzyme by the anionic surface charge. The
dissociation constant Kd for PLA2 bound to DMPC vesicles
is 3 mM which decreases with the mole fraction of the products
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activation by the interfacial anionic charge is 15-fold [54]. The
forward and reverse steps of the E to E⁎ equilibrium control the
effect of bile salts on the rate. Its description requires knowledge
of the partition coefficients of bile salts, as well as the mole
fraction of the accumulated product and their distribution in the
vesicle population during the course of the reaction progress.
These variables of the interfacial surface charge density
determine the fraction of PLA2 in the catalytically active E⁎
form which is assumed to be constant after the onset of the
stationary phase reaction progress. Values of these variables in
the microenvironment of E⁎ are not known. For ensemble
averaging of the turnover events at the interface during the pre-
burst rate we assume that the variables are also averaged by the
conditions in the reaction mixture.
Modeling of the falling phase requires the assumption that
PLA2 forms a specific EB (or E⁎B) complex that effectively
competes out the activated E⁎ state. The results show that KEB,
the dissociation constant of EB, is such that it would promote
the E⁎ EB shift at equilibrium. However, the measured
value of KEB (ca 5 μM) is not sufficiently low, or the estimated
concentration of B in the aqueous phase is not sufficiently high,
to compete with the strongly interface-bound E⁎ complex.
Thus, the falling phase may be dominated by an inactive E⁎B
complex in the interface that forms when B binds specifically to
E⁎ without disrupting interfacial binding.
Two of the fits in Fig. 4 are for the models (A:a and A:b)
where E⁎B dominates in the falling phase of the effect of
TCDOC. Assuming ideal partitioning, the falling phase cannot
be reproduced with EB alone. Depending on the solute, the ratio
of E⁎B to EB could change. In model B it is assumed that the
partitioning of bile salt is non-ideal and saturated at high
concentration, but the biphasic effect is observed only with EB
formed in solution. Without independent evidence it is not
possible to choose one of these models, nor can it be ruled out
that they may be related at the mechanistic level. There is
uncertainty about the second order effects related to the non-
ideal partitioning, distribution and dispersity of the products and
the additives in the bilayer. Rigorous interpretation of the
reaction progress with significant amounts of products formed
in situ would require understanding of the local concentration,
distribution and phase mixing of the products and bile salts, and
their effects on the PLA2 binding and activation.
3.4. Additional constraints for modeling kinetic effects of bile
salts
The boundary conditions for modeling the mono- and
biphasic effects of bile salts are provided by the results and
controls outlined below. For the calculation of the mole fraction
of the added bile salt, we assume that bile salts are distributed on
both sides of DMPC bilayer. Even if it is not so, the kinetic
effects of bile salt are not due to asymmetric distribution
because comparable reaction progress were observed with 0.06
mole fraction cholate codispersed with DMPC before the
formation of vesicles. Also the reaction progress for the
hydrolysis of DMPC with or without added bile salt is notnoticeably affected by the transmembrane potential induced by
gradients of K+, Na+ or Ca2+ ions with valinomycin, monensin,
or A23187 (calcimycin), respectively.
The monophasic or biphasic effects of bile salts on the
PLA2-catalyzed pre-burst rate are essentially complete below
0.15 mole fraction bile salt in DMPC vesicles. Such effects of
less than 0.25 mole fraction cholate or TCDOC are not
noticeable on the processive interfacial turnover rate in the
scooting mode on DMPM vesicles [23,39], or on micelles of
short chain phosphatidylcholines at high salt concentration in
the pseudo-scooting mode [41]. These results show that the
kinetic contribution of the surface dilution of substrate by bile
salts is small. It is consistent with KM⁎=0.35 mole fraction for
DMPM [23] or 0.65 mole fraction for phosphatidylcholines
[41]. Comparable kinetic effects of competitive inhibitors with
these substrates also show that the bile salts do not change the
KI⁎ to KM⁎ ratio [16,34]. These results rule out a direct effect of
bile salts on the interfacial turnover parameters KM⁎ or kcat⁎.
Allosteric activation of KM⁎ by the interface and kcat⁎-activation
by surface charge is explicitly considered for modeling the rate
activation.
The monophasic and biphasic kinetic effects of bile salts on
DMPC vesicles are not due to mixed-micellization or a change in
the organization of the bilayer. The rate decrease due to mixed
micellization is observed if the substrate replenishment becomes
rate-limiting [16,36]. In our assay the kinetic effect of bile salt is
essentially complete below 0.15 mole fraction (Fig. 3), whereas
vesicle disruption and mixed-micellization begin at N0.3 mole
fraction bile salt [55,56]. Also, the CMC of bile salts (0.8 to
5 mM range) do not correlate with the onset of the rising phase,
or the peak rate, or the bile salt concentration at the peak rate.
TCDOC lowers the PLA2 catalyzed rate of hydrolysis of
dioctanoylphosphatidylcholinemicelles with 2mMCaCl2 under
the low-salt conditions where the enzyme is not fully kcat⁎-
activated [41]. In this assay, cholate does not have a significant
effect. The effect of cholate versus TCDOC is also different with
POPC+bile salt (3:7 mole ratio) substrate [40], where the initial
linear region of the reaction progress is the stationary-phase
reaction progress. In this assay, the initial rate of hydrolysis of
POPCwith cholate is 150 s−1 compared to 15 s−1 with TCDOC,
which is comparable to the difference at 0.1 mole fraction
cholate versus TCDOC in DMPC vesicles (Fig. 3).
The kinetic effects of bile salts on the hydrolysis of DMPC
vesicles are not due to the gel–fluid phase change or the
formation of mixed micelles. Anomalous effect of the gel–fluid
thermotropic phase change on the delay during the hydrolysis of
saturated phosphatidylcholine vesicles is dramatic and well
characterized [16,18,19]. These effects are not seen on the burst
rate of hydrolysis of DMPC containing the products, or the
processive turnover rate on DMPM vesicles [57,58]. Also both
below and above the transition temperature of 24 °C for DMPC
vesicles, the rate increase is monophasic with cholate and
biphasic with TCDOC (results not shown). Between 16 and
29 °C the peak rate increases about 10-fold with both bile salts
with no anomalous effect at the phase transition temperature.
The maximum rate with TCDOC is at 0.013 mM at 16 °C, and
at 0.13 mM at 29 °C.
Fig. 6. Concentration (log scale) dependence of the effect of (filled diamonds)
masticadienolic acid, (triangles) ezetimibe and (circles) TCDOC on the
normalized rate of hydrolysis of 1 mM DMPC vesicles containing 0.05 mM
cholate by pig pancreatic IB PLA2; and also (squares) the effect of ezetimibe on
the hydrolysis of DMPM.
2483B.-Z. Yu et al. / Biochimica et Biophysica Acta 1768 (2007) 2478–24903.5. The rate-lowering effect of TCDOC depends on the 62–66
loop of PLA2
If the kinetic effect depends on the structure of the bile salt
(Fig. 3), selectivity is also expected from the structure of PLA2.
Results in Fig. 5a show that the rate of hydrolysis by human
pancreatic IB PLA2 increases with cholate, and the rate increase
with TCDOC is just noticeable. In Fig. 5b, the rate-lowering
effect of TCDOC is not seen with the ΔPLA2 mutant of pig
PLA2 in which the 62–66 loop is deleted. For ΔPLA2 the
monophasic rate increase with cholate is comparable to WT but
with a modest shift to lower concentration and with 40% lower
peak rate. Also the cholate and TCDOC concentration de-
pendence of the DE2 PLA2 (from venom of Naja melanoleuca)
catalyzed rate of hydrolysis of DMPC is monophasic (results
not shown). DE2 PLA2 is evolutionarily without the 62–66
loop [59]. These results suggest that the 62–66 loop in
pancreatic PLA2 has evolved for selective binding of the rate
lowering bile salts, presumably via an effect on the binding of
the second calcium and allosteric kcat⁎-activation. The pre-burst
rate for the hydrolysis of DMPC vesicles by PLA2 increases 10-
fold when the second calcium binding is saturated with kinetic
KCa
2 =5 mM. For the E71N mutant, the rate activation is about 4-Fig. 5. (a) The rate of hydrolysis of 1 mM DMPC vesicles by human IB PLA2
with added (squares) cholate or (triangles) TCDOC. As also shown the rate at
0.05 mole fraction cholate changes with added (circles) TCDOC or (diamonds)
ezetimibe. (b) Rate of hydrolysis of DMPC (1 mM) vesicles by ΔPLA2 (PLA2
with 62–66-loop deleted) with added (squares) cholate or (triangles) TCDOC.fold with KCa
2 =1.8 mM (results not shown). These results are in
accord with the KCa
2 values for the hydrolysis of dioctanoylpho-
sphatidylcholine micelles by E71N and D66D mutants [60].
3.6. Structural selectivity of the rate-lowering compounds
The origin of the rate-lowering effect via a specific site on
PLA2 predicts a structural selectivity that would be different
than the effect of competitive inhibitors [16,17,34]. This
expectation is affirmed by results in Fig. 6 where TCDOC,
ezetimibe, and masticadienolic acid lower the pre-burst rate of
hydrolysis of DMPC in the presence of 0.05 mM cholate. Note
that the rate-lowering efficacies of ezetimibe and TCDOC are
different with human (Fig. 5a) and pig PLA2 (Fig. 6). Score of
other compounds, including aristolochic acid and aspirin that
cocrystallize with PLA2 [61], did not show an effect on the pre-
burst rate or the processive interfacial turnover rate. Of the rate-
lowering compounds, only masticadienolic acid has a modest
affinity for the active site of pig PLA2 with 50% inhibition of
processive turnover on DMPM vesicles at 0.02 mole fraction
[62]. Analogs of masticadienolic acid could be useful as mixed-
inhibitors to study coupling of the bile-salt binding site with the
active-site events. Also of interest are the components [32] of
guggul resin of Commiphora mukul that has hypolipidemic
effect [63,64]. About 70% of its PLA2 rate-lowering activity is
extracted (Soxhlet) with hexane and remains in the nonvolatile
fractions. Further fractionation showed that the activity is
mainly due to six out of more than 100 components in the
extract. Among the compounds that we have identified so far
cambrenes were significantly more active than guggulosterones.
Together these results suggest that the rate-lowering effect is
due to the formation of a specific complex with PLA2 at the
interface rather than the aqueous phase (Appendix).
3.7. Specific binding of bile salt to PLA2 mutants
Several independent methods showed that bile salts form EB
in the aqueous phase. Isothermal calorimetric results in Fig. 7a
Fig. 7. (a) Exothermic heat change on the titration of 8.5 μM PLA2 with
(diamonds) cholate or (triangles) TCDOC. Fit parameters (obtained by including
the depletion of TCDOC titrant) are: KEB 9 μM, ΔH-12 kcal/mole, S, 3.5 cal/
mole/deg. Results not shown gave for TUDOC KEBb2 μM, ΔH-16 kcal/mole;
UDOC, KEB 37 μM, ΔH-12 kcal/mole; and for TDOC, KEB 38 μM, ΔH-
14 kcal/mole. (b) TCDOC concentration dependent change in the Trp emission
(355 nm) intensity of PLA2 mutants: From top (up triangles) W3F/R6W,
(squares), WT/3W, (diamonds) W3F/M20W, and (inverted triangles, bottom)
W3F/K10W. The fits are for a single hyperbola and the parameters are
summarized in Table 2.
Table 1
Binding parameters a for the binding of TCDOC and TDOC to Trp-mutantsof
PLA2
Mutant TCDOC Tauro-DOC
KEB δFmax KEB δFmax
WT(3 W) 6 0.15 30 0.11
proPLA2 27 0.20
Δ62–66 41 0.13
R6 M 150 0.05 N100
K10 M 8 0.07 N100
R6M/K10 M ? 0.02 10 0.1
A1W/W3F 210 0.67 0
L2W/W3F 18 0.23 0.02 −0.02
R6W/W3F 50 0.30 4 −0.07
K10W/W3F 4 −0.24 10 −0.27
L19W/W3F 3 0.13 44 0.26
M20W/W3F 75 −0.01 2 −0.02
K53W/W3F 15 −0.22 33 −0.06
K56W/W3F 21 −0.025 35 −0.06
K63W/W3F 3 0.11
K87W/W3F 200 −0.02 2 −0.02
a Uncertainty in the parameters, if ∣δFmax∣ N0.05, is 20% with r2 N0.9.
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TCDOC, but no heat change is observed with cholate. Results
with TCDOC could be fitted to a single hyperbola with apparent
KEB of 9 μM. ITC titration with TUDOC, TDOC or UDOC
gave KEB values in the 2 to 40 μM range with enthalpy change
of −12 to −16 kcal/mole. These results suggest that the binding
of the rate-lowering bile salts is largely enthalpy driven with a
modest entropy change.
As shown in Fig. 7b, titration of PLA2 with TCDOC is
accompanied by a modest change in the Trp emission of PLA2
and Trp-mutants. Cholate had no effect on the emission from
Trp-3 or Trp-6 (results not shown). The change in the Trp-3
emission intensity with TCDOC concentration is adequately
fitted to a single hyperbola with Hill coefficient of 1±0.2. KEB
for TCDOC is modestly lower and δFmax is higher at pH 4 than
at pH 8. The effect of TCDOC on the Trp-3 emission does not
depend on the presence of calcium. As summarized in Table 1
KEB values for TCDOC and TDOC are noticeably different for
the mutants, and the maximum change in the intensity δFmaxdepends on the position of Trp in the mutant. Trp-substitution
near the N-terminus has a significant effect on KEB suggesting
that the (1,10)-helix plays a role in the binding of B. KEB for
ΔPLA2 is larger, which is consistent with the result that
TCDOC does not show the rate-lowering effect with ΔPLA2
(Fig. 5b). However, the change in KEB alone cannot
quantitatively account for the loss of rate-lowering effect
suggesting that the kinetic effect is due to E⁎B. It is not unlikely
that the specificity for the bile salt binding to the E form may
qualitatively parallel the binding to the interface bound forms of
the enzyme (Scheme A1).
Bile salts do not significantly protect catalytic H48 from
alkylation in the presence or absence of calcium [65,66]. For
example, in the presence of 0.2 mM cholate or TCDOC the
alkylation time increases by about 15% both in the presence or
absence of calcium. Also accessibility of Trp-3 for the
quenching by succinimide or the oxidation by N-bromosucci-
nimide [31] does not change noticeably in the presence of
0.2 mM bile salts. These results suggest that the EB complex is
formed without binding of bile salt to the active site, and that
bile salts do not cluster on the i-face.
3.8. Rate-lowering bile salts quench fluorescence of TMA-DPH
bound to PLA2
Results in Fig. 8 show that the rate-lowering bile salts
quench the fluorescence signal from TMA-DPH bound to
PLA2. The decrease in the signal intensity depends on the
concentration as well as the structure of the bile salt. The rank
ordering in Fig. 8 compares favorably with the rate-lowering
effect of the bile salts at 0.1 mM (Fig. 3), i.e. in both assays
cholate is least effective and TUDOC and TCDOC are most
effective. The signal from TMA-DPH bound to free PLA2 or to
EB and Ei
# is not significantly influenced by the binding of
calcium to the catalytic site, or by the occupancy of the active
Table 2
Changes in the Trp-emission spectra associated with the formation of the Ei
#
complexes of PLA2 with decylsulfate
Mutant without TCDOC with 0.2 mM TCDOC
WT(3 W) E1
#, E2
# E2
#
3 W/6 M E1
#, E2
# E1
#, E2
#
3 W/10 M E1
#, E2
# none
3 W/6,10 M E1
#, E2
# E1
#, E2
#
6 W E1
#, E2
# E2
#
10 W none E2
#
19 W E1
#, E2
# E2
#
20 W E1
#, E2
#, E3
# E1
#, E2
#, E3
#
Fig. 9. Decylsulfate concentration dependent change of the emission intensity
from 1 μM TMA-DPH mixed with 1 μM PLA2 (diamonds) alone or containing
0.2 mM (circles) TCDOC or (squares) DOC at pH 6.9 in EGTA buffer. In the
absence of PLA2 the signal intensity increases above the CMC suggesting that
the signal intensity increases by the partitioning of the probe.
Fig. 8. Effect of bile salts on the signal at 445 nm (excitation 280 nm) from an
equimolar mixture of PLA2 and TMA-DPH (1 μM each) in 2 mM calcium and
10 mM Tris at pH 8.0. The rank order for the apparent bile salt concentration for
50% quenching is (from top): cholateNDOCNglycoDOCNurso-DOCNTauro-
DOCN tauocheno-DOCN taurourso-DOC. These changes are not observed with
W3F mutant (not shown).
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mental conditions, possibly because several factors contribute
to the signal. For such reasons it is not possible to model and
analyze the TMA-DPH quenching results [42,45].
Available evidence suggests that TMA-DPH remains bound
to the enzyme in the EB and Ei
# complexes. The signal from
TMA-DPH bound toΔPLA2 is considerably smaller. Therefore
it appears that the quenching of the probe signal is due to a
change in the local energy transfer environment. This
interpretation is consistent with the effect of cholate on TMA-
DPH bound to Trp-mutants. Cholate has a modest effect on the
signal from TMA-DPH bound to PLA2 with Trp-3 (Fig. 8), yet
cholate significantly quenches the signal from TMA-DPH
bound to the 10W, 19Wand 20 W substitution mutants of W3F
PLA2 (results not shown). We conclude that both cholate and
TCDOC interact with PLA2 in the aqueous phase with
significantly different consequences on the environment of
TMA-DPH bound to PLA2.
3.9. Amphiphile interactions of PLA2 in the presence of bile
salts
Formation of a single EB complex of PLA2 with bile salt is
noticeably different than the decylsulfate binding behavior.
Sequential and cooperative binding of decylsulfate to the i-face
of PLA2 to form three premicellar Ei
# complexes is described as
[45]:
E⇆
þN1 VA
n1;K1
E#1⇆
þN2 VA
n2;K2
E#2⇆
þN3 VA
n3;K3
E#3
Decylsulfate does not bind to the active site, however binding
of active site directed inhibitors is allosterically activated in E2
#
and E3
#. Therefore it is of interest to examine if bile salts and
other rate lowering compounds influence the decylsulfate
binding to PLA2 Table 2. Results with mixtures of am-
phiphiles are of interest also because Model A1 (Appendix)involves interactions of PLA2 with wide ranging amphiphiles
at the interface.
As shown in Fig. 9, TCDOC, DOC, or cholate (results not
shown) modify the decylsulfate binding monitored as the
change in the signal from TMA-DPH bound to PLA2. In the
absence of bile salt, the effect of decylsulfate is biphasic [45].
The quenching up to about 0.3 mM decylsulfate is due to the
formation of E1
# that is apparently not influenced by 0.2 mM
DOC or cholate. In the presence of 0.2 mM TCDOC, the signal
from PLA2+TMA-DPH is small, and it changes little up to
0.3 mM decylsulfate. This is expected if TMA-DPH bound to
PLA2 is quenched with TCDOC (Fig. 8) or with decylsulfate
(Fig. 9), i.e. TCDOC and decylsulfate have a comparable effect,
and the effect of cholate and DOC is different.
As also shown in Fig. 9 in the presence of TCDOC and DOC
the signal increase above 0.5 mM parallels the formation of E2
#
and E3
# but at lower concentration than with decylsulfate alone.
The difference in the environment of TMA-DPH in these
premicellar complexes suggests a difference in the energy
transfer efficiency associated with the cooperative binding of
decylsulfate enhanced by both the bile salts. This interpretation
is qualitatively consistent with other results. As shown in Fig.
10, intramolecular energy transfer from W3 to anthranoloxy
acceptor covalently bound to K87 [67] is significantly modified
in the presence of other amphiphiles below their CMC. Here the
Fig. 10. Decylsulfate titration curves for 1 μM 87-anthranaloxy-PLA2 alone
(circles), or in the presence of 1 μM WT PLA2 without any other amphiphile
(unfilled circles), or in the presence of 0.25 mM diheptanoyl phosphatidylcho-
line (filled squares), or 0.2 mM cholate (unfilled triangles), or 0.2 mM TCDOC
(filled diamonds) in pH 8 Tris buffer containing 0.05 mM Zn2
+. Characterization
of the labelled PLA2 and the controls for the interpretation of results are
described before [67,68].
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are within the energy transfer distance. Thus results in Fig. 10
show that the E2
# complexes with decylsulfate are clustered, and
E1
# and E3
# complexes are not. The shift in the presence of
cholate and TCDOC suggests that both promote the decylsul-
fate binding to the i-face. Additional shift is observed in the
presence of diheptanoylphosphatidylcholine which is bound to
the active site but it is not hydrolyzed in the presence of Zn2+
[68]. Similar qualitative effects of bile salts are apparent in the
decylsulfate titration curves with the Trp mutants. These results
are also supported by the isothermal calorimetric titration where
the decylsulfate binding curve changes to different extents in the
presence of TCDOC as well as DOC or cholate.
4. Discussion
The rate-lowering effect of certain bile salts on the pancreatic
PLA2 catalyzed hydrolysis of phosphatidylcholine vesicles is a
novel kinetic phenomenon. We suggest that the mono- and
biphasic kinetic regulation by bile salts and other dietary
components is relevant to the gastrointestinal processing of
phospholipids that could ultimately control the uptake and
excretion of fats and cholesterol. Structural specificity of the
rate-lowering effect of bile salts and other compounds provides
leads for the design of drugs that could potentially modulate
gastrointestinal cholesterol and fat uptake via a well character-
ized molecular target. The broader significance of the kinetic
effects of bile salts, and the major issues that remain to be
addressed, is discussed below.
4.1. Physiological significance
It is certain that the dietary fat emulsion changes with
gastrointestinal passage, however detailed understanding of
the state of the physiological substrate of pancreatic PLA2 is
lacking. The likely target of PLA2 secreted by pancreas is thephospholipid monolayer on the surface of the fat emulsion
modified by bile salts. The monolayer on the emulsion surface
would contain amphiphilic phospholipids and cholesterol,
whereas nonpolar cholesterol esters and glycerides will be
sequestered in the hydrophobic core. Thus modification of the
emulsion by bile salts and resulting changes in the interfacial
activity of the lipolytic enzymes could influence the fat ab-
sorption and excretion [3,13,15,25]. This expectation is
consistent with the result that PLA2 inhibitors [1,12] and the
PLA2 knockout mice [3] promote excretion of dietary fat. The
PLA2 rate-lowering effect of ezetimibe and guggul components
may also be related to their effects on fat uptake. It is however
intriguing that ezetimibe lowers the gastrointestinal uptake
of dietary cholesterol but not the uptake of other lipidic com-
ponents [29]. Such effects of ezetimibe are attributed to its
glucuronylated form, which may also be related to other
systemic effects of ezetimibe including potentiation of the effect
of statins by inhibiting its efflux [29,69–71]. Also at concen-
trations N20 μM, well above its aqueous solubility limit,
ezetimibe is reported to bind to acylCoA-cholesterol acyltrans-
ferase, apical drug efflux pumps, aminopeptidase N, and to a
Niemann–Pick C1 like protein which appears to be involved in
the intestinal cholesterol uptake.
4.2. Relationship of bile salt binding to the i-face events
TCDOC does not lower the ΔPLA2 catalyzed rate, which
suggests that the 62–66 loop in pancreatic PLA2 has evolved
for regulation by bile salts. Also the 57–72 loop regulates the
low affinity calcium binding that increases the pre-burst rate in
the presence of bile salts. The assay conditions to characterize
the kinetic effect of bile salts are optimized to take advantage of
the kinetic contribution of the loop and the second calcium site.
This loop could also play a role in the charge compensation of
anionic K53 and K56 by the anionic interface that leads to
allosteric kcat⁎ activation [54]. Several residues on this loop form
the i-face which could control the active site via the hydrogen-
bonding network.
It remains to be determined how the binding of certain bile
salts interferes with the kcat⁎-activation step. Available results
provide some insight. Enhanced decylsulfate binding to the i-
face results not only from the occupancy of the active site, but
also in the presence of bile salts. If bile salts bind to an
independent regulatory site, the extent of allosteric activation
from such binding could depend on the structure of the
amphiphile bound to the regulatory site. Thus the challenge is to
model and characterize interplay between the active site, i-face
and the bile salt binding site.
4.3. Kinetic effect of bile salts
The zwitterionic phospholipid bilayer interface used to
monitor the biphasic effect of bile salts on the pre-burst rate
mimics the monolayer interface of dietary emulsion. One of the
key conditions for the kinetic consequences modeled in this
paper (Appendix) is high Kd for PLA2 bound to such
zwitterionic interface. Kd controls both the rate increase and
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binding (lower Kd) and kcat⁎-activation of the bound enzyme by
the anionic charge on the interface. The rate-lowering effect is
due to the reversal of E⁎ to EB, (EB)⁎ or E⁎B complex in which
B is bound to a specific site that impairs turnover rate. Other
mechanisms, including non-ideal partitioning of bile salts, are
plausible but cannot be tested at this stage. Potent hydrophobic
rate-lowering compounds are likely to be ideally and nearly
completely partitioned in the interface, and therefore their
complex with the enzyme at the interface has impaired turnover
rate. Weight of the available evidence with PLA2 suggests that
the rate-lowering effect is dominated by catalytically impaired
E⁎B which may be kinetically related but not identical to EB in
the aqueous phase. Although not conclusive, such processes that
control the interface-to-interface exchange of enzyme are useful
for a general understanding of the kinetic regulation of stationary
phase reaction progress of interfacial enzymes [16,18,19].
The pre-burst rate increases 15 fold in the presence of certain
bile salt (Fig. 3), as also seen with other anionic amphiphiles
[5,6,16,17,19,50]. The effect of anionic B⁎ in the interface on
Kd is modeled with:
Kd ¼ K0d=½1þ ðXB=KÞn
where n is the number of B⁎ interactions that give the interface-
activated E⁎ for the interfacial turnover. Thus with n=5 at
XB=K=0.03 mole fraction, Kd would be lower by a factor of
two. Kd would be 32-fold lower at XB/K=2. On DMPM
interface the surface charge density corresponds to XB=1. With
XB/KN30, the Kd would be subnanomolar, which is consistent
with the highly processive interfacial turnover in the scooting
mode [23,57,72]. Structurally, n=5 is consistent with the five
anion binding sites on the i-face of PLA2 [73].4.4. Bile salts bind to PLA2 at the interface
Results with premicellar complexes suggest that decylsulfate
binding is altered but not blocked in the presence of bile salts.
Also activation of active binding and the chemical step is
observed with E2
# and E3
# complexes in the absence or presence
of bile salts but not with EB or E1
# complexes. Beyond this we
have not found a reliable way to characterize the interaction of
the rate-lowering compounds with PLA2 at the interface.
Properties of EB show a parallel with the interfacial kinetic
effects of bile salts which suggests that a comparable complex
may also be formed at the interface under the kinetic conditions.
Since many of the rate-lowering compounds are very hydro-
phobic, they would also form interfacial complexes, and it is
unlikely that their concentration in the aqueous phase could be
sufficient for desorbing the bound enzyme to the aqueous phase.
E in the aqueous phase is neither identical to the premicellar
Ei
# nor to the interface-activated E⁎ form of PLA2. It can be
speculated that EB and its premicellar complexes differ from
the (E⁎), E⁎B and (EB⁎) forms postulated in Appendix to
model the kinetic effects of the bile salts. We also do not know
the microscopic variables that control the underlying equilibria
between such states in the interface or in the premicellar com-plexes. Within such limitations, premicellar complexes with
decylsulfate provide insights. For example bile salts do not
interfere with but domodify the stepwise and cooperative binding
of decylsulfate to the i-face of PLA2. Also bile salts do not
interfere with the binding to the active site of PLA2 in the
premicellar complexes. These results suggest that specific binding
of bile salts could modulate the function of the allosteric site for
the kcat⁎-activation of E⁎S [54]. Formation of EB and Ei
# does not
require calcium that is obligatorily required for the occupancy of
the active site. However, binding of inhibitors to the active site is
activated with the formation of E2
# but not of EB or E1
#.
4.5. Non-ideal partitioning and other possibilities
Biphasic effect of TCDOC is also predicted with certain
assumptions about its non-ideal partitioning and distribution in
the interface. There is no reliable method to measure partition
coefficient of bile salt in vesicles, let alone test the non-ideality
assumption. It is still worth considering the possible signifi-
cance of non-ideal partitioning because it could be relevant
under certain conditions or may be responsible for some
second-order effects especially in the context of the emulsion
properties. As mentioned above, the mole fraction of anionic B⁎
in the zwitterionic interface controls Kd. For the sake of
argument, if B⁎ is present only in the outer monolayer of
vesicle, its asymmetric expansion would saturate when more B
cannot be accommodated in relation to the inner monolayer or
the core of the emulsion. If such surface saturation occurs at
about 0.04 mole fraction and mixed-micellization occurs at
N0.2 mole fraction, added B in the middle range could:
(a) Remain in the aqueous phase and participate in the E to
EB equilibrium.
(b) Or extra B could still accumulate in the interface in a
different form that participates in the E⁎ to E⁎B
equilibrium.
Such possibilities are neither mutually exclusive nor unique.
Also without independent evidence they cannot be distin-
guished from second order kinetic effects.
To recapitulate, regulation of pancreatic PLA2 activity by
bile salts provides a viable basis to understand the physiological
role of pancreatic PLA2 and bile salt. In this search, kinetic
results, as well as the properties of EB and other premicellar
complexes, have provided significant functional and structural
insights into the coupling of the active-site events with other
interactions. Understanding of the bile salt binding site of E⁎B
or EB will be useful for realizing the pharmacological potential
of the pancreatic PLA2 as a target for the regulation of fat and
cholesterol homeostasis.
5. Note added in proof
Y. Pan and B. Bahnson (J. Mol. Biol. 369, 439–450, 2007)
have reported that there is no discernible effect of bile salt
structure crystallographic structure of their complex with PLA2.
As developed in this paper these results are not consistent with
2488 B.-Z. Yu et al. / Biochimica et Biophysica Acta 1768 (2007) 2478–2490the activation or the PLA2 rate lowering efficacies of bile salts,
and they do not even correlate with the solution properties of the
EB complexes.
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Appendix A. The kinetic model
The reaction diagram (A1) between enzyme (E), bile salt (B)
and lipid includes most of the enzyme states that have been
identified [16,17]: E is enzyme free in solution, EB is the
specific and stoichiometric enzyme–bile–salt complex in
solution; (E)⁎ is enzyme bound at the vesicle surface without
activation, E⁎ is the fully activated enzyme interacting with a
number of B-molecules in the interface. The branch (ES)⁎
describes the low enzyme activity in the absence of bile salt (or
product) and E⁎S is the fully activated branch.
ðA1Þ
Scheme A1: Paradigm for the kinetic effects of bile salts. The
top row shows the solution states, the middle row shows the
interface-associated states that have not developed the
activating interactions with B⁎. The leftmost column shows
all states with a B-molecule bound specifically; these con-
tribute only for some bile salts, e.g. TCDOC. All binding para-
meters necessary for the calculations are shown in this diagram.
Key boundary conditions within this paradigm are experimen-
tally described in the text and analytically modelled in the
appendix.
If the state (EB)⁎ in Scheme A1 is removed from
consideration, the binding polynomial for the enzyme is
Z ¼ 1þ Bf
KEB
þ M
K0d
1þ 1 XB*
K0M
þ XB*
Ka
 n
1þ 1 XB*
KM*
þ XB*
KEB*
  
ðA2aÞ
and the initial stationary (steady-state) phase turnover rate for
the enzyme:
v ¼ M
K0d
k0cat
1 XB*
K0M
þ kcat* XB
*
Ka
 n
1 XB*
KM*
 
1
Z
ðA2bÞHere XB
⁎ is the mole fraction of bile salt in the interface, and Bf
its free concentration in solution. The factor 1−XB⁎ describes
the dilution of substrate in the interface due to partitioning of
bile salt; there could also be a contribution from a steady-state
presence of product which has been neglected in this equation.
M=1 mM is the concentration of DMPC (if we consider only
the concentration of accessible lipid in the outer layer, this
number would be ca. 0.6 mM and some parameter values would
change in a similar way).
A.1. Partitioning of B
The dependence of the turnover on the total concentration of
added bile salt, BT, depends crucially on the mode of
partitioning of bile salt in the vesicles. Assuming that each
molecule of B that binds in the interface removes N lipids from
further binding (saturable binding sites), one finds:
XB* ¼ 12 d
ðN þ 2ÞBT þM þ K V
ðN þ 1ÞðBT þMÞ þ K V
 1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 4BT½ðN þ 1ÞðBT þMÞ þ K V½ðN þ 2ÞBT þM þ K V2
s( )
ðA3aÞ
and
Bf ¼ BT MXB*=ð1 XB*Þ ðA3bÞ
K′ is the dissociation constant for B from the interface
(partitioning). Setting N=−1 in Eq. (3) recovers the expression
for ideal partitioning where Bf =K′XB
⁎ holds. If partitioning is
saturable with N=30 there would be a maximum XB
⁎ =0.03.A.2. Stationary rates in the presence of bile salts
As there are no clean ways of measuring the amount of bile
salt in the interface, we have tested the model calculations in
two extreme limits: (A) Ideal partitioning (N=−1 in Eq. (3))
where XB
⁎ and Bf increase throughout the whole range of added
B; (B) saturable binding where XB
⁎ increases to a maximum
level around 0.03 (N=32 in Eq. (3)) and Bf in solution is nearly
zero until this limit is reached and excess B enters solution only
thereafter. Both pictures can be used to describe the bile–salt
dependence of the PLA2 turnover on DMPC vesicles, albeit
with different sets of assumptions (cf. Fig. 4).
With addition of TCDOC or cholate, the turnover shows a
cooperative increase around 25 μM that can be described in the
reaction scheme, Eq. (1), as an interfacial activation step due to
enzyme–bile salt interactions with Hill parameter n=5 and
Ka=0.025–0.035 mole fraction. Addition of more bile salt
leads to a levelling off of activity in the case of cholate and to a
sharp downturn in activity in the case of TCDOC. With ideal
partitioning this downturn could come from the specific
binding of B to E⁎ forming the inactive E⁎B complex in the
interface. The different behaviour of cholate could come from
the fact that cholate does not form the specific EB or E⁎B
complexes. For one set of calculations (model A above) we
assume that the downturn for TCDOC is caused by formation
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downturn mimicking the effect of TCDOC in the falling phase
from a 1:1 complex with B as shown in Fig. 4 where the dotted
line is for a 1:1 complex and a better fit (solid line) can be
achieved by introducing a Hill number 1.5 for the formation of
E⁎B from E⁎.
In a second set of calculations (model B above) we assume
saturable partitioning of bile salt in the interface; then the
interpretation of the biphasic turnover in the presence of
TCDOC is more straightforward. EB can start to compete with
the active E⁎ complex only when the concentration of B in
solution starts to build up after the partitioning has been
saturated. This would give a sharp downturn in enzyme activity
in the presence of TCDOC, but not for cholate which does not
form EB (Fig. 2). The theoretical curve with saturable
partitioning shown in Fig. 4 (dashed line) is from Eqs. (A2)
and (A3) using N=27 in Eq. (A3a). Other parameter values
used are K′=0.02 mM, Kd
0 =3 mM, kcat⁎=240 s
−1, kcat
0 =20 s−1,
KM
0 =KM⁎=0.65 mole fraction, Ka=0.023 mole fraction, n=5;
with TCDOC, solid curve, KEB=0.005 mM and KEB⁎≫1
assumed. The parameter space is large and the curves are not
best fits; they were generated from reasonable assumptions and
adjustments of parameter values from the experimental results
(if available) and chosen such that the difference in Fig. 4
between TCDOC and cholate can be described by a single
parameter: the specific KEB for EB or KEB⁎ for E⁎B. Also note
that the parameters K′, Kd
0, kcat⁎/kcat
0 , KM⁎ and KEB have been
determined independently. Substrate interactions with unac-
tivated (KM
0 ) and unactivated (KM⁎) enzyme are assumed to be
comparable because differences in KM
0 have very little influence
on the overall rate.
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